CoLucid pockets $4M for PhIII migraine drug trial

CoLucid Pharmaceuticals has injected some capital into its R&D tank with a $4 million funding tranche. The company has plans to drive toward a Phase III trial of lasmiditan, its lead drug for treating migraines, late next year, the Triangle Business Journal reports. The Durham, NC-based developer tapped Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures for the financing. Report

Suggested Articles

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.

Less than two years after taking the reins from founding chief Rusty Williams, Five Prime Therapeutics CEO Aron Knickerbocker is exiting the company.